- Home
- IMNN vs SONM Comparison
IMNN vs SONM Comparison
Compare IMNN & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNN | SONM |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 7.5M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMNN | SONM |
|---|---|---|
| Price | $2.83 | $3.18 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $182.61 | N/A |
| AVG Volume (30 Days) | ★ 51.7K | 18.8K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $58,298,000.00 |
| Revenue This Year | N/A | $127.68 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $0.52 |
| 52 Week High | $9.32 | $12.30 |
Technical Indicators
Market Signals| Indicator | IMNN | SONM |
|---|---|---|
| Relative Strength Index (RSI) | 37.75 | 40.43 |
| Support Level | $0.48 | $0.64 |
| Resistance Level | $3.16 | $7.08 |
| Average True Range (ATR) | 0.23 | 0.50 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 40.00 | 41.46 |
Price Performance
Historical ComparisonAbout IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About SONM Sonim Technologies Inc.
DNA X Inc operates a digital asset management platform.